Reviva Pharmaceuticals' CEO will discuss schizophrenia treatment advances in an upcoming webinar on October 10, 2025.
Quiver AI Summary
Reviva Pharmaceuticals Holdings, Inc. announced that its CEO, Dr. Laxminarayan Bhat, will participate in a fireside chat and webinar on October 10, 2025, hosted by A.G.P./Alliance Global Partners. The event will focus on the challenges faced by patients with schizophrenia and will highlight the phase 3 clinical data of Reviva's lead drug candidate, brilaroxazine. Notable experts Dr. Larry Ereshefsky and Dr. Mark Opler will join the discussion, which will be moderated by James Molloy of A.G.P. Attendees can register for the event, and a replay will be available on Reviva's investor webpage afterward. Reviva specializes in developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases, with two drug candidates, brilaroxazine and RP1208, currently in its pipeline.
Potential Positives
- Reviva Pharmaceuticals is participating in a fireside chat and KOL webinar, which enhances its visibility and engagement with key stakeholders in the pharmaceutical industry.
- The discussion will focus on the phase 3 clinical data of its lead drug candidate brilaroxazine for treating schizophrenia, highlighting the company's commitment to addressing significant unmet medical needs.
- Reviva has secured composition of matter patents for its drug candidates in multiple regions, underlining the innovative nature and potential market exclusivity of its therapies.
Potential Negatives
- The press release does not provide any updates on financial performance or funding, which could indicate potential concerns about the company's financial health or ability to support ongoing research and development.
- There is no mention of any recent clinical trial successes or significant advancements in their drug development process, which may raise questions about the progress of their lead drug candidate, brilaroxazine.
- The focus on a KOL webinar might suggest a lack of substantial news to share regarding product development or partnerships, potentially reflecting stagnation in the company's operational progress.
FAQ
What is the date and time of the Reviva webinar?
The Reviva webinar is scheduled for October 10, 2025, at 11:00 AM ET.
Who will be participating in the Reviva fireside chat?
Laxminarayan Bhat, PhD, and KOLs Dr. Larry Ereshefsky and Dr. Mark Opler will participate.
What topics will be covered in the Reviva webinar?
The webinar will discuss the treatment landscape for schizophrenia and phase 3 clinical data of brilaroxazine.
How can I register for the Reviva webinar?
You can register for the event by clicking the registration link provided in the press release.
Where can I find the webinar replay?
A replay of the webinar will be available in the investor section of Reviva’s website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners' James Molloy.
To register for the event, please click here . A replay of the webinar will be accessible in the investors section of Reviva’s website following the event.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
[email protected]
